Abstract: The present invention provides clinically applicable, safe and convenient, pharmaceutical compositions and methods for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment methods comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.

Abstract: A surgical method for delivering a drug solution to myocardium includes the steps of: inserting a catheter into at least one of a coronary artery and a coronary vein, the catheter having a lumen, a lateral opening connecting the lumen and outside of the catheter, and a radiopaque marker indicating a position of the lateral opening; rotating the catheter while observing the marker such that an orientation of the lateral opening becomes a predetermined orientation with respect to a treatment target site; projecting a puncture needle through the lateral opening; piercing a myocardium of the treatment target site with the puncture needle; and injecting a drug solution containing therapeutic cells or chemical compounds from the puncture needle into the myocardium.

Abstract: The present invention provides a facility capable of efficiently performing work while maintaining the cleanliness of a location where an article is manufactured, when manufacturing of the article and other work are performed in parallel concurrently; and an implementation method for manufacturing an article by using the facility. The facility comprises a clean room 1, multiple work booths 2 provided inside the clean room 1 and each comprising an entrance and exit, and barrier sections provided along entrances and exits of the multiple work booth 2 and configured to prevent airflow from the outside to the inside through the entrances and exits. The area inside each of the multiple work booths 2 has the same grade of cleanliness as the area that is outside the multiple work booths 2 but is inside the clean room 1.

Abstract: An object is to provide a pharmaceutical composition that improves cardiac function when administered during coronary artery bypass surgery for ischemic cardiomyopathy. A pharmaceutical composition for improving cardiac function comprising: (A) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin 12 receptor agonist, the PLGA having an average molecular weight of 10000 to 30000; and (B) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin 12 receptor agonist, the PLGA having an average molecular weight of 40000 to 60000.